The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I can't see a particular reason for the weak share price recently. Yes, Canaccord sold a chunk in June but the share price recovered from that... yet we are back at 3750p to sell. Strange. Results in October as usual... I think all is well.
More than decent surely ? Boost to share price suggests someone very impressed.
Decent results during a difficult period.
Should see better movement in the sp over the next 12 months.
Interim Results due Monday 29.03.21 - per Company website.
https://www.bioventix.com/investors/overview/
If the sp stays up today, that will be four consecutive days that is has risen.
Accept that, nor the rise is exceptional, but it is nice to see a few days of upward movement.
Wondering if it's anything to do with the testing of the new variant Covid 19 virus.
The presentation packs and recording from our webinar with Bioventix can be found here for full members to view: https://www.sharesoc.org/seminar/sharesoc-webinar-with-bioventix-bvxp-28-october-2020/
To access the presentation, you'll need to be a full member of ShareSoc, which is a not-for-profit organisation that supports individual shareholders and campaigns for shareholder rights. If you're not already a member you can join here: https://www.sharesoc.org/membership/
Once you've joined, you'll receive an invitation to register for our "members network" private social network, from where you'll be able to access the presentation (and presentations on 100s of other meetings). If you're already a member and have any difficulty accessing the report, please do not hesitate to contact us here: https://www.sharesoc.org/contact-us/
Current shareholders and potential investors may be interested in our webinar with Bioventix. More information and registration here: https://www.sharesoc.org/events/sharesoc-webinar-with-bioventix-bvxp-28-october-2020/
Hi Rooky,
With the new results the P/E goes down to 27. Very reasonable considering it has strong growth and it is not affected by the slow down to much. Not to mention the special dividend and dividend. I make that 141p for the year and a 3.3% div yield.
This is the sort of share to buy and hold. Also the total issued shares has not changed by much for the last 5 years. So you are not getting diluted for this growth.
Hi shares123,
Shows how under the radar this company is, with this being only the 3rd post since the results were released, whereas several other companies with similar M cap would have a couple of pages of comments/posts.
At a P/E of 37, some might see it as being over priced, whereas those of us who have been following for a while, see it as a proof of it's future prospects.
I see someone sold 64k worth and another couple of sells in the 20k plus areas, but I never begrudge people taking a profit, which those sells look like.
As for my investment, will continue to hold as long as the general trend is upward and onward.
Wonderfull results I have bought back in. The growth has been from the T3 and anti- drug testing antibody in the UK and rest of the world/china. From R&D projects and product revenue. It seems whenever they can see a revenue drop (e.g. testosterone/estradiol/NT-proBNP) testing they seem to be able to go out and get new R&D projects from their partners to fill the revenue gap. Anti-Troponin antibody role out is very slow but it is building.
Results, beat expectations, which in this Covid effected times, is very good.
When you look deeper, the Covid situation has had a negative effect, due to the significant reductions in tests that use the companies product.
In fact todays papers, indicate that the figures for none related Covid cases being treated in UK hospitals (serious cases) show a 90% reduction, which of course has to relate to the companies own figures re blood testing for these serious illnesses.
I know of several Cancer diagnosies that have been either delayed, or/and after diagnosis, further delays in treatment, which again has to include recurring blood tests.
So as the company states, once thing 'get back to normal' the companies prospects look even more exciting.
Then there is the dividend of 52p, with the special div of 53p, so !05p, what's not to like.
Well they go Ex Div on the 31st of this month so a rise until then would seem reasonable, I bought these in January and nothing much seems to faze the SP. Also I noticed they have paid a special Dividend in some previous years so an added bonus if they can keep that going.
One of the few shares I have held that have never gone below my buy price, having bought in April of this year.
Of course since my buy, it has been up and down, but never from memory, up more than £1.50p per share.
With todays current increase of £1.60p, just wondering if this is about to lift above £43 before month end.
You are overlooking their work on corona virus
Looking through the companies last presentation they warn that COVID may affect the use of core antibodies in the lab.
The Vit D antibody is 52% of revenue for example. The others are related to non-emergency thryoxine testing and fertily testing mainly. The hospitals and doctors have had non-critical use significantly reduced during the COVID crisis. I think the next set of results will show a big down turn in revenue.
big purchase 20000 sharese
dropped some more ,had hoped would move up today
, ncyt seeing a move up ,looking like may be start of a run up with share price there again
if that happens hoping other covid shares might move up as well
still hoping bvxp s p might soon se a tick up
will a blue finish be seen today
share price only slightly in red today
hoping next week might share price moving back up more at bvxp
will bvyt gain from interest that looks to be building at ncyt ,on social media and across share boards with the Roche test sales demand news as well as the sales rns expected at ncyt their next week , if a rise there will it help other covid shares
is now a good entry point for someone not invested anyone who knows this company well!
WRITE up in sharescope the system i use rates this company says perfect
another strong day today
Yes very warren Buffett just the sort of shares I like. Preferably in a business easy to understand
like a share where a good dividend is paid
and with a strong cash position
I recommend reading the RNS of the interim results dated 30 march. An allusion to the virus pithy and to the point. They are involved all right. Also note cash position huge increase in dividend etc